The receptor for the IL-35 cytokine closely associated with Tregs can be used to develop methods to block or augment IL35R signaling to block or boost, respectively, IL-35 activity. This could be used to treat autoimmune and inflammatory diseases. Methods that block/inhibit IL35R signaling could be used to treat any condition in which the IL-35-mediated activity of Tregs is shown to blocking/limiting disease resolution such as cancer and chronic inflammatory disease.
Receptor,IL-35 cytokine ,Tregs, autoimmune and inflammatory disease, cancer
Granted Patents or Published Applications
US patent 10,392,431
Related Scientific References
We are currently seeking licensees in all fields for the development of this technology. Contact: firstname.lastname@example.org.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.